Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 131, Issue 16
April 19 2018
Issue Cover

Table of Contents

BLOOD COMMENTARIES

CLINICAL TRIALS AND OBSERVATIONS
Improving on R-ICE in relapsed DLBCL
Clinical Trials & Observations
Sarit Assouline
View Articletitled, Improving on R-ICE in relapsed DLBCL
IMMUNOBIOLOGY AND IMMUNOTHERAPY
Awakening exhausted NK cells in lymphomas
Lapo Alinari
View Articletitled, Awakening exhausted NK cells in lymphomas
Lymphoid Neoplasia
Gene mutations in lenalidomide-treated CLL
Francesca Romana Mauro,Robin Foà
View Articletitled, Gene mutations in lenalidomide-treated CLL
MYELOID NEOPLASIA
A fellowship of Ring1 maintains AML stem cells
David M. Heery
View Articletitled, A fellowship of Ring1 maintains AML stem cells
MYELOID NEOPLASIA
Ups and downs of CHIP
Koichi Takahashi
View Articletitled, Ups and downs of CHIP
TRANSPLANTATION
Pathogenic neutrophils in acute GVHD
Paul J. Martin
View Articletitled, Pathogenic neutrophils in acute GVHD

PERSPECTIVE

Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents
Xiaohong Ruby Xu,George M. Yousef,Heyu Ni
View Articletitled, Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents
Supplemental data

BLOOD SPOTLIGHT

Hepcidin agonists as therapeutic tools
Carla Casu,Elizabeta Nemeth,Stefano Rivella
View Articletitled, Hepcidin agonists as therapeutic tools

REVIEW ARTICLE

Enhancer dysfunction in leukemia
Anand S. Bhagwat,Bin Lu,Christopher R. Vakoc
View Articletitled, Enhancer dysfunction in leukemia

CLINICAL TRIALS AND OBSERVATIONS

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
Clinical Trials & Observations Brief Report
Craig S. Sauter,Matthew J. Matasar,Heiko Schoder,Sean M. Devlin,Pamela Drullinsky,John Gerecitano,Anita Kumar,Ariela Noy,Maria L. Palomba,Carol S. Portlock,David J. Straus,Andrew D. Zelenetz,Susan J. McCall,Shoshana T. Miller,Amanda I. Courtien,Anas Younes,Craig H. Moskowitz
View Articletitled, A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Frank Vari,David Arpon,Colm Keane,Mark S. Hertzberg,Dipti Talaulikar,Sanjiv Jain,Qingyan Cui,Erica Han,Josh Tobin,Robert Bird,Donna Cross,Annette Hernandez,Clare Gould,Simone Birch,Maher K. Gandhi
View Articletitled, Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Supplemental data

LYMPHOID NEOPLASIA

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide
Clinical Trials & Observations
Koichi Takahashi,Boyu Hu,Feng Wang,Yuanqing Yan,Ekaterina Kim,Candida Vitale,Keyur P. Patel,Paolo Strati,Curtis Gumbs,Latasha Little,Samantha Tippen,Xingzhi Song,Jianhua Zhang,Nitin Jain,Philip Thompson,Guillermo Garcia-Manero,Hagop Kantarjian,Zeev Estrov,Kim-Anh Do,Michael Keating,Jan A. Burger,William G. Wierda,P. Andrew Futreal,Alessandra Ferrajoli
View Articletitled, Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide
Supplemental data

MYELOID NEOPLASIA

Ring1A and Ring1B inhibit expression of Glis2 to maintain murine MOZ-TIF2 AML stem cells
Haruko Shima,Emi Takamatsu-Ichihara,Mika Shino,Kazutsune Yamagata,Takuo Katsumoto,Yukiko Aikawa,Shuhei Fujita,Haruhiko Koseki,Issay Kitabayashi
View Articletitled, Ring1A and Ring1B inhibit expression of Glis2 to maintain murine <em>MOZ-TIF2</em> AML stem cells
Supplemental data
Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT
CME Clinical Trials & Observations
Gerbrig Berger,Leonie I. Kroeze,Theresia N. Koorenhof-Scheele,Aniek O. de Graaf,Kenichi Yoshida,Hiroo Ueno,Yuichi Shiraishi,Satoru Miyano,Eva van den Berg,Hein Schepers,Bert A. van der Reijden,Seishi Ogawa,Edo Vellenga,Joop H. Jansen
View Articletitled, Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT
Supplemental data

TRANSPLANTATION

Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset
Jan Hülsdünker,Katja J. Ottmüller,Hannes P. Neeff,Motoko Koyama,Zhan Gao,Oliver S. Thomas,Marie Follo,Ali Al-Ahmad,Gabriele Prinz,Sandra Duquesne,Heide Dierbach,Susanne Kirschnek,Tim Lämmermann,Martin J. Blaser,Brian T. Fife,Bruce R. Blazar,Andreas Beilhack,Geoffrey R. Hill,Georg Häcker,Robert Zeiser
View Articletitled, Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset
Supplemental data

LETTER TO BLOOD

Identification of novel recurrent CPSF6-RARG fusions in acute myeloid leukemia resembling acute promyelocytic leukemia
Tianhui Liu,Lijun Wen,Hongjian Yuan,Yi Wang,Li Yao,Yang Xu,Jiannong Cen,Changgeng Ruan,Depei Wu,Suning Chen
View Articletitled, Identification of novel recurrent CPSF6-RARG fusions in acute myeloid leukemia resembling acute promyelocytic leukemia
Supplemental data

BLOOD WORK

Testicular double-hit lymphoma in a patient with history of follicular lymphoma with high proliferation index
Betty M. Chung,Arthur W. Zieske
View Articletitled, Testicular double-hit lymphoma in a patient with history of follicular lymphoma with high proliferation index

ERRATUM

Farrell AT, Goldberg KB, Pazdur R. Flexibility and innovation in the FDA’s novel regulatory approval strategies for hematologic drugs. Blood. 2017;130(11):1285-1289.
View Articletitled, Farrell AT, Goldberg KB, Pazdur R. Flexibility and innovation in the FDA’s novel regulatory approval strategies for hematologic drugs. <em>Blood.</em> 2017;130(11):1285-1289.

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

Detection and evolution of preleukemic clones
CME
View Articletitled, Detection and evolution of preleukemic clones
  • Cover Image

    Cover Image

    issue cover

    Acute myelogenous leukemia is organized as an aberrant developmental hierarchy maintained by leukemia stem cells. Ring1A and Ring1B repress expression of Gli-similar 2 (GLIS2) to maintain leukemia stem cells. The image shows leukemia cells stained with anti-GLIS2 (red) after deletion of Ring1A and Ring1B and cell nuclei stained with 4′,6-diamidino-2-phenylindole (blue). See the article by Shima et al on page 1833.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkTable of Contents
  • PDF Icon PDF LinkBack Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma
Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation
Prothrombotic Antibodies Targeting the Spike Protein's Receptor-Binding Domain in Severe COVID-19
The Contribution of the Monocyte‐Macrophage Lineage to Immunotherapy Outcomes

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals